Fig. 3From: MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemiaCorrelation analysis of MLL2/KMT2D and MLL3/KMT2C. MLL2/KMT2D and MLL3/KMT2C gene expression for each CML patient (Spearman Correlation test, p < 0.0001, r = 0.9121, CI 95%)Back to article page